Histoplasmosis Treatment Market Trends

Growth Drivers

• Cost-effective developments and health enhancement: The increased demand for improvement in healthcare quality is effectively impacting the histoplasmosis treatment market adoption. According to a 2022 economic burden analysis by the CDC (published by NLM in March), fungal diseases, including histoplasmosis, cause significant hospitalizations and outpatient visits, with an average loss of 13.4 workdays per histoplasmosis hospitalization, highlighting the impact of timely diagnosis and treatment on reducing morbidity and costs. This is evidently relevant for immunocompromised populations, wherein a delay in diagnosis results in poor outcomes. Besides, hospitals are integrating rapid antigen testing and have successfully achieved a reduction in misdiagnosis rates, thus suitable for the market’s growth.
• Current trends in government and personal expenditure: Antifungal treatment expenditure under Medicaid has grown consistently, with total spending on superficial fungal infections (SFIs) medications rising from USD 121.9 million in 2009 to approximately USD 155 million in 2023. Invasive fungal infection (IFI) medication spending peaked at USD 156.8 million in 2022 before moderating to USD 80.7 million in 2023, reflecting shifts in usage and drug prices. On the other hand, government spending is increasing due to rising fungal disease cases and immunocompromised populations. These trends highlight the expanding opportunity in the histoplasmosis treatment market’s growth.
• Increased immunocompromised patient populations: The leading driver behind the demand for histoplasmosis treatment is the increasing size of immunocompromised populations at risk for disseminated disease. This encompasses patients with advanced HIV/AIDS, organ transplant recipients taking immunosuppressants, and those taking biologic treatments for autoimmune diseases. For instance, the NLM June 2025 study stated that 78% of the symptomatic histoplasmosis cases had affected immunocompromised individuals, mostly those with HIV, indicating higher susceptibility and severity among them. This trend necessitates broader drug availability and diagnostic capabilities in both developed and emerging healthcare systems.

Total Direct and Indirect Costs in Histoplasmosis Treatment

Source: NLM, June 2025

Challenges

• Diagnostic underusage among endemic nations: Despite suggestions from the WHO, primary care facilities across histoplasmosis-based areas have access to antigen evaluation, which has caused a hindrance in the histoplasmosis treatment market. Besides, the 2023 CDC Morbidity Report has demonstrated that the registered cases in the U.S. are frequently misdiagnosed, which tends to delay the treatment procedure by nearly a month. Besides, the disease prevalence has increased to in Brazil, and only public hospitals are able to perform confirmatory testing, thereby creating a gap in the market’s upliftment.
• Vulnerabilities in API-based supply chain: The histoplasmosis treatment market is experiencing supply constraints for API, with international antifungal APIs stemming from only manufacturers in India. As per an article published by the FDA in 2023, import alerts on major suppliers have resulted in a half-year shortage of amphotericin B, especially in the U.S., which has pressured rationing in hospitals. This issue effectively compounds in developing nations, based on which the PAHO reported that Latin America has witnessed stockouts of itraconazole as of 2023, owing to delays in India’s export compliance, thus negatively impacting the overall market.